Managing the Morbidity: Individualizing Risk Assessment, Diagnosis, and Treatment Options for Upper Extremity Lymphedema

Giacomo Montagna; Andrea V Barrio

doi:10.1016/j.soc.2023.05.004

Managing the Morbidity: Individualizing Risk Assessment, Diagnosis, and Treatment Options for Upper Extremity Lymphedema

Surg Oncol Clin N Am. 2023 Oct;32(4):705-724. doi: 10.1016/j.soc.2023.05.004. Epub 2023 Jun 25.

Authors

Giacomo Montagna¹, Andrea V Barrio²

Affiliations

¹ Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA.
² Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA. Electronic address: barrioa@mskcc.org.

PMID: 37714638
DOI: 10.1016/j.soc.2023.05.004

Abstract

In the setting where breast cancer-related lymphedema (BCRL) remains a feared and common complication of breast cancer, here we review important factors for the development, diagnosis, prevention, and treatment of BCRL. We find that race/ethnicity affect BCRL development risk, that future studies should focus on understanding the biological reasons behind the increased susceptibility of certain racial minorities to BCRL, that surveillance, early detection, exercise programs, and arm compression can reduce the risk of BCRL, and that surgical techniques to preserve and restore lymphatic drainage being evaluated in randomized trials may become transformative in reducing BCRL risk for high-risk patients.

Keywords: Breast cancer-related lymphedema; Early intervention; Neoadjuvant chemotherapy; Racial disparities; Relative volume change; Risk factors; Screening; Surgical treatment.

Publication types

Review

MeSH terms

Breast Neoplasms* / complications
Female
Humans
Lymphedema* / diagnosis
Lymphedema* / etiology
Lymphedema* / therapy
Morbidity
Risk Assessment
Upper Extremity